CP-237 Analysis of survival in patients diagnosed with metastatic breast cancer treated with eribulin in a tertiary hospital
| Autor: | S. de la Fuente, J Lopez Santamaria Donoso, A Gago, P Montejano Hervas, I Reyes, B Isla-Tejera |
|---|---|
| Rok vydání: | 2017 |
| Předmět: |
Oncology
medicine.medical_specialty education.field_of_study business.industry Population Vinorelbine medicine.disease Metastatic breast cancer Surgery Capecitabine chemistry.chemical_compound Regimen Breast cancer chemistry Internal medicine medicine Progression-free survival education business medicine.drug Eribulin |
| Zdroj: | Clinical pharmacy. |
| DOI: | 10.1136/ejhpharm-2017-000640.235 |
| Popis: | Background Eribulin is indicated for the treatment of patients with locally advanced or metastatic breast cancer who have progressed after at least one chemotherapeutic regimen for advanced disease. However, in our hospital its use is limited to a subgroup of patients with resistance to capecitabine and vinorelbine who have previously received treatment lines including taxanes and anthracyclines. Purpose The aim was to analyse the effectiveness of eribulin for the treatment of metastatic breast cancer in a clinical setting. In addition, we explored factors that might influence survival of patients treated. Material and methods Following an observational retrospective design, data for patients who received at least one dose of eribulin from February 2014 to July 2016 were obtained from the computerised physician order entry system. A data collection form was designed to record patient’s demographics, time since diagnosis, sites of metastases, previous lines of treatment, number of cycles of eribulin, progression free survival (PFS) and overall survival (OS) adjusted by age, previous treatment lines (anthracyclines, taxanes, capecitabine and vinorelbine), administration of subsequent lines, and types and number of metastases. Statistical analysis and data visualisation were performed using the R programming language. Results Clinical data for 40 patients (97.5% women, 54 years old (range 33–85)) were reviewed. With a median time since breast cancer diagnosis of 8.1 years, they had received a median of 4.6 (range 2–7) treatment lines. We detected that most patients did not fulfil local criteria for eribulin use (67.5%). However, they received 3.5 (range 1–16) cycles for metastatic disease (locations were 75% bone, 50% lung, 65% liver and 10% brain). Median PFS was 2.4 months (0.5–16.5) and OS with 45% of events was 4.2 months (0.5–20.5). 17.5% of patients died before 3 months. Only liver metastases predicted OS (hazard ratio 4.495; 95% CI 1.011–19.99; p=0.031). Conclusion In our case, the effectiveness of eribulin in the clinical setting was modest. PFS and OS values were lower than published in the literature. Survival analysis did not identify a subgroup of patients that could benefit from this treatment in our population. No conflict of interest |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|